Navigation Links
Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries
Date:9/4/2013

WALTHAM, Mass., Sept. 4, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions. Financial details are undisclosed but include milestone payments and royalties on future entinostat sales. Details of the agreement include:

  • Eddingpharm receives exclusive rights to develop, market and sell entinostat in mainland China, Hong Kong, Thailand, Macau, Taiwan, Malaysia and Singapore
  • Eddingpharm receives rights to manufacture entinostat
  • Syndax will receive royalties on future entinostat sales
  • Eddingpharm may participate in entinostat's first three global Phase 3 registration trials
  • A joint development committee will oversee conduct of any trials
  • A joint commercialization committee will oversee marketing
  • Eddingpharm can explore further indications for entinostat in China
  • All data will be shared by both companies for regulatory purposes

"We look forward to working closely with Syndax to develop entinostat in breast and lung cancer as well as other indications," said Xin Ni, chairman and chief executive officer of Eddingpharm. "We are focused on bringing new and effective treatments to patients in our Asian communities and we believe this partnership with Syndax has the potential to help a large number of cancer patients across our Asian markets."

Arlene M. Morris, Syndax's chief executive officer added, "We view this agreement as the start of an important collaborative effort between our two companies. The agreement to a joint development committee, trial participation and sharing of data represents Eddingpharm's important commitment to that effort. The result will be a cooperative effort that has the potential to impact many patients in China suffering with advanced, treatment-resistant cancers."

About Entinostat

Entinostat, Syndax's lead product candidate, has been studied in more than 800 cancer patients where objective tumor responses have been observed in both solid and hematologic malignancies. Entinostat's established safety and efficacy profile as both a single agent and in combination with a number of commercially available targeted therapies differentiates it from other histone deacetylase inhibitors(HDACi). Having demonstrated promising clinical results in breast and lung cancer, entinostat is moving toward pivotal clinical testing. It is an oral, novel inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression. This aberrant gene expression can result in reversible, epigenetically-based drug tolerance. Designed to selectively target the HDAC isoforms most relevant to the biology of tumors, entinostat can normalize dysregulated gene expression in cancer cells, thereby restoring sensitivity to targeted therapy. Entinostat is the first HDACi with positive results in a randomized Phase 2 study in breast cancer and is the only HDACi in late-stage development for this indication.

About Eddingpharm

Founded in 2001, Eddingpharm is a leading specialty pharmaceutical company in the fast growing China market, committed to actively introducing quality products into China's pharmaceutical market. The Company focuses on the development and promotion of pharmaceutical products in four therapeutic areas: medical nutrition, oncology, anti-infective and respiratory.  Eddingpharm has established long-term cooperative relationships with a number of multinational pharmaceutical companies and overseas specialty pharmaceutical companies, and has built up a competitive product portfolio and pipeline in the four major therapeutic areas. Eddingpharm recently established its US affiliate and set up a product development team with R&D capabilities in Los Angeles, CA, USA, to coordinate and communicate with leading global R&D institutions and explore opportunities for introducing innovative pharmaceutical products in China. The Company currently employs over 700 people.

More information can be found on www.eddingpharm.com.

About Syndax Pharmaceuticals

Syndax is focused on employing epigenetic strategies to overcome the problem of resistance in oncology care in solid tumors. The company holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor in late-stage clinical development for the treatment of advanced breast cancer and lung cancer. A randomized, placebo-controlled Phase 2 study of entinostat in combination with aromatase inhibitors in breast cancer (ENCORE 301) demonstrated an improvement in both progression-free survival and overall survival, providing the basis for the evaluation of entinostat in pivotal Phase 3 testing in metastatic breast cancer. Entinostat also demonstrated promising results in a subset of non-small cell lung cancer patients when given in combination with the EGFR-TKI erlotinib (ENCORE 401). NCI and Syndax are collaborating on the development of entinostat under a Cooperative Research and Development Agreement aimed at improving survival in advanced, hard-to-treat cancers.

For more information, visit www.syndax.com.

Corporate Contact: 
Bob Goodenow 
Chief Business Officer 
Syndax Pharmaceuticals 
(781) 419-1418 
BGoodenow@Syndax.com

Media Contacts: 
David Schull or Matt Middleman, M.D. 
Russo Partners 
(212) 845-4271 
(212) 845-4272 
david.schull@russopartnersllc.com 
matt.middleman@russopartnersllc.com


'/>"/>
SOURCE Syndax Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
2. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
3. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
4. Ruggles Family Foundation and Mr. and Mrs. Rudy L. Ruggles, Jr. Make $1.25M Donation to J. Craig Venter Institute for New Study to Identify and Elucidate Healthy Aging Biomarkers
5. Simcere Pharmaceutical Group Enters Into Definitive Merger Agreement for Going Private Transaction
6. Texas Childrens Hospital establishes the Jeffrey Modell Diagnostic & Research Center with a donation from the Jeffrey Modell Foundation
7. Fountain Valley Regional Medical Center Becomes Orange Countys First Hospital Awarded Advanced Certification In Inpatient Diabetes Care
8. Athens Regional Medical Center Boosts Patient Safety with Expanded Use of Capnography
9. CVS Caremark Hosts Grand Opening of State-of-the-Art Mail Service Pharmacy and Customer Center
10. INTERPHEX and Parenteral Drug Association Announce Agreement
11. Piramal Imaging Provides Comments in Response to the Centers for Medicare and Medicaid Services (CMS) Proposed Coverage Decision for Beta-Amyloid Positron Emission Tomography (PET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 Acquisition ... Sciences, Product Development Capabilities in North ... Base . Indegene ( http://www.indegene.com ... the acquisition of Skura Corporation,s life science business. ... adaptive sales enablement technology for life science organizations ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... , April 28, 2016 ... insights on healthcare, announced today that it has been ... Cool Vendor in Life Sciences, 2016, ... 2016.  The report focuses on life-science- oriented analytics, algorithms ... from patients and doctors, confirm medication ingestion, and analyze ...
Breaking Medicine Technology:
(Date:5/2/2016)... Fla. (PRWEB) , ... May 02, 2016 , ... ... fat,” wraps itself around major organs, such as the kidneys, liver and pancreas. ... Robert Drapkin, M.D ., a board-certified physician in Internal Medicine, Medical Oncology and ...
(Date:5/2/2016)... ... May 02, 2016 , ... According to an American Psychological Association ... sexually abused before the age of 18. Of those who survive, many still face ... others. , In her new book, Lyah! Lyah! Pants on Fyah!, she shares ...
(Date:5/2/2016)... ... , ... TeleMedCo™, a new company developing real time technology ... rapid diagnosis, triage and admission of patients leveraging IBM Watson’s software and healthcare ... the first time at GENBAND’s Perspectives16 conference. , TeleMedCo selected GENBAND’s Kandy ...
(Date:5/2/2016)... ... ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city where ... 5 US Cities with the Highest Plastic Rates .” The other cities that made ... calculated using a survey by RealSelf and combining that data with the number ...
(Date:5/2/2016)... ... 2016 , ... For many artists, the act of blending paint is based ... a science. , Using the new, highly precise METTLER TOLEDO ML204T balance to ... and meaning to his works. What’s more, it has allowed him to recreate these ...
Breaking Medicine News(10 mins):